Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1222 Intradermal Booster After CoronaVac (COVID-19)
TCTR20210817003Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Aug 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoints: Immunogenicity after intradermal AZD1222 booster, Reactogenicity of intradermal AZD1222 booster and 1 more. Started Aug 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210817003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210817003.